Billiontoone Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $397.4M+160.5% YoYTTM through 30 Jun 2026
Net Income $37.7MTTM through 30 Jun 2026
Free Cash Flow $33.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 68.0% |
| EBITDA Margin | 12.6% |
| Operating Margin | 5.3% |
| Net Margin | 9.5% |
Returns
7.0%ROE
5.2%ROA
83.1%ROIC
Balance Sheet Health
Debt / Equity0.11x
Current Ratio11.69x
Net Debt-$438.7Mnet cash position
Cash & Equivalents$548.6M
Quality Metrics
Altman Z-Score18.28
Piotroski F-Score7 / 9
FCF Margin8.3%
Rule of 4023.1
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $305.1M
Diluted EPS$1.03TTMFY2025: $0.35
Dividend
No dividend
Capital Allocation
R&D Spend$59.2M
Capex Intensity3.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Prenatal Clinical Testing | View detailsStrong growth driven by high adoption rate of the UNITY Screen among maternal-fetal medicine specialists. | ||
| Oncology Clinical Testing | View detailsRapidly scaling segment with significant growth potential in the oncology market, though currently carrying lower margins due to subscale volumes. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.